Article

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of…

Drug Design, Development and Therapy · 2018 · Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A

Key facts

Title Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
First author Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A
Journal Drug Design, Development and Therapy
Published Jan 23, 2018
DOI 10.2147/DDDT.S141491
Devices mentioned K852441, K854177, K854178, K854179, K854180, K854181, K854182, K854183, K854184, K854185, K854186, K854187 and 1 more
Product codes mentioned CDT, CEO, CGA, CGX, CHH, CIG, CIS, CIX, CJE, CKA, KLB, KLS and 1 more

At a glance

  • 10–99 FDA submissions mentioned
  • 10–99 Product codes mentioned

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About Literature

Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.

Source: Publisher and PubMed metadata; device mentions identified by Orca1

Browse all Literature